
    
      Subjects will be evaluated regularly for safety. Subjects will return for a follow-up visit
      30-33 days after the last dosing of study drug. Subjects who tolerate the drug and who do not
      experience progressive disease, intolerable toxicity, or meet any of the other withdrawal
      criteria - may continue to receive Nerofe & Doxorubicin for up to 5 cycles, at the discretion
      of the Principal Investigator. Throughout the trial, oversight will be provided by the
      Clinical Safety Committee (CSC).
    
  